https://orcid.org/0000-0002-4696-0643
-
Views
-
Cite
Cite
Athanasios Fountas, Niki Karavitaki, Response to commentary “Vasopressin deficiency following operated craniopharyngiomas: fear or fatality?”, European Journal of Endocrinology, Volume 191, Issue 5, November 2024, Pages R1–R3, https://doi.org/10.1093/ejendo/lvae137
Close - Share Icon Share
Extract
We would like to thank Sahakian et al.1 for their commentary and for their positive remarks on the extensive amount of work underpinning our manuscript.2 We understand that the authors have concerns about our data on vasopressin deficiency (AVP-D) in patients operated for craniopharyngioma and provide their views on this topic. This is indeed an interesting field, but we would like to respectfully respond to their comments and clarify inaccuracies included in the commentary.
The authors mention that “there is evidence that prevalence of AVP-D increases dramatically after surgery, up to 60-90% in children and 50-70% in adults” and provide as reference the paper by Gaillard et al.3 Unfortunately, these results cannot be found in the quoted study, in which, notably, patients aged under 16 years were excluded. In this series of 79 adults, 29 had AVP-D pre-operatively, and new AVP-D developed in 26 extra cases (after transsphenoidal surgery [TSS] or craniotomy). Overall, AVP-D was present in 37% of patients pre-operatively and was persistent in 67% of total cases post-surgery.
